Status: Recruiting
A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.
Participants needed: 300
Trial details
Age: 6+Biological sex: AllType: ObservationalSponsor: ITF Therapeutics LLCUpdated: Jul 2, 2026Locations: 9
Eligibility criteria
Patients of any gender at least 6 years of age, diagnosed with DMD (according to... [+3]
Patient previously received givinostat (commercial or investigational product) a...